Collaboration: Co-developed by Aptevo Therapeutics and Alligator Biosciences under a collaboration agreement signed in 2017. ALG.APV-527 was built using Aptevo’s ADAPTIR bispecific technology platform and combines binding domains sourced from Alligator Biosciences’ ALLIGATOR-GOLD® human scFv library.
Broad Utility: 5T4 is a well-defined tumor antigen expressed on many different types of malignancies including, non-small cell lung, renal, pancreas, prostate, breast, colorectal, gastric, ovarian and cervical cancers. Conversely, 5T4 has limited expression on normal tissues, making it an attractive target for cancer immunotherapy.
Reduced Toxicity: ALG.APV-527 employs a novel mechanism of action to direct the therapeutic 4-1BB immune response towards the tumor, thereby potentially reducing the harmful side effects of systemic immune stimulation while providing a strong tumor-directed immune activation. ALG.APV-527 contains an Fc that does not interact with Fc gamma receptors, it has the potential to be less toxic than 1st generation monospecific 4-1BB antibodies.